# A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)

> **NCT04524403** · PHASE2 · COMPLETED · sponsor: **Corcept Therapeutics** · enrollment: 150 (actual)

## Conditions studied

- Antipsychotic-induced Weight Gain (AIWG)

## Interventions

- **DRUG:** Miricorlilant
- **DRUG:** Miricorlilant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04524403
- **Lead sponsor:** Corcept Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-09
- **Primary completion:** 2022-07-29
- **Final completion:** 2022-08-25
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2024-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04524403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04524403, "A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04524403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*